RT Journal Article
SR Electronic
T1 Diagnostic Performance and Characteristics of Anterior Nasal Collection for the SARS-CoV-2 Antigen Test: A Prospective Study in Japan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.03.21252425
DO 10.1101/2021.03.03.21252425
A1 Takeuchi, Yuto
A1 Akashi, Yusaku
A1 Kato, Daisuke
A1 Kuwahara, Miwa
A1 Muramatsu, Shino
A1 Ueda, Atsuo
A1 Notake, Shigeyuki
A1 Nakamura, Koji
A1 Ishikawa, Hiroichi
A1 Suzuki, Hiromichi
YR 2021
UL http://medrxiv.org/content/early/2021/03/05/2021.03.03.21252425.abstract
AB We conducted a prospective study in Japan to evaluate the diagnostic performance of the antigen test QuickNavi-COVID19 Ag using anterior nasal samples and to compare the degrees of coughs or sneezes induction and the severity of pain between anterior nasal collection and nasopharyngeal collection. A total of 862 participants were included in the analysis. In comparison to the findings of reverse transcription PCR using nasopharyngeal samples, the antigen test using anterior nasal samples showed 72.5% sensitivity (95% confidence interval [CI]: 58.3%-84.1%) and 100% specificity (95% CI: 99.3%-100%). Anterior nasal collection was associated with a significantly lower degree of coughs or sneezes induction and the severity of pain in comparison to nasopharyngeal collection (p < 0.001). The antigen test using anterior nasal samples showed moderate sensitivity but was less painful and induced fewer coughs or sneezes.Competing Interest StatementDenka Co., Ltd., provided fees for research expenses and the QuickNavi-COVID19 Ag kits without charge. Hiromichi Suzuki received a lecture fee from Otsuka Pharmaceutical Co., Ltd., regarding this study. Daisuke Kato, Miwa Kuwahara and Shino Muramatsu belong to Denka Co., Ltd., the developer of the QuickNavi-COVID19 Ag.Funding StatementDenka Co., Ltd., provided fees for research expenses and the QuickNavi-COVID19 Ag kits without charge.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of TMCH approved the present study (approval number: 2020-033).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are not publicly available due to their containing information that could compromise the privacy of research participants.